Issuu on Google+

A NEW DIRECTION IN IMMUNOTHERAPY

TAP is the Next Step in the fight against Cancer and Infectious Diseases

Corporate Presentation April 2012


CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company's plan of operations and finances, the potential for the Company's vaccines and proposed clinical trials.

The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.


TAPIMMUNE MARKETS

Immunotherapy • Treatment that uses body’s own immune system to fight disease • Major new therapeutic option

Market validated by recent approvals • Provenge® (Dendreon), first approved therapeutic vaccine for prostate cancer • Yervoy® (BMS), first approved antibody against T-regulatory cells for melanoma

Focus on cancer & infectious disease • HER2/neu breast cancer – Phase I clinical • Antiviral/smallpox - Animal efficacy

$Billion Markets


TAPIMMUNE TECHNOLOGY

TAP Expression Platform •

Unique patented platform technology  cancer & infectious disease

Addresses major gap in cancer vaccine development  recognition and killing by cytotoxic T-cells

• •

Platform for viral diseases New direction in immunotherapy

Major Step Forward in new Vaccine Development” Plos Pathogens Editorial


CREATING A LEADING IMMUNOTHERAPY COMPANY • Founded as Public Corporation OTCBB – TPIV •

Spin-off from UBC, Vancouver BC

Breakthrough research/core IP

• Changed into a Development Company • Re-located to Seattle in 2010 •

Leading immunotherapy community

State of the art laboratory facilities

• Collaborations with Mayo Clinic •

Licensing of proprietary antigens

1551 Eastlake Avenue, Seattle, WA 98102 206-905-7783 www.tapimmune.com

First clinical trial to begin Q2 2012

1

• Management , Advisory & Technical Team •

Leaders in cancer, infectious disease, product development, IP


HIGHLY EXPERIENCED MANAGEMENT TEAM Glynn Wilson PhD Chairman & CEO 25 years experience in product development

Mark Reddish VP Development 25 years experience in cancer vaccines/biodefense Biomira, ID

SmithKline Beecham, Ciba-Geigy, Tacora

Biomedical, Baxter, Bayer AG

Bob Florkiewicz PhD Sr. Director Virology/Molecular Biology UW, GSK, Seed IP Law Group

Denis Corin President & CFO

Venissa Izaguirre Project Manager FHCRC, Cell Therapeutics

Novartis, Beckman Coulter


ADVISORS AND COLLABORATORS ◦ ◦ ◦ ◦ ◦ ◦ ◦

Mac Cheever (Corixa; Fred Hutchinson Cancer Center) Lynn Depippo (Sherbrook Capital Management) George Cardona (Strategic Advisor to Board) Sailesh Barcha (Advisor to Board) Keith Knutson (Mayo Clinic) Greg Poland (Mayo Clinic) Puget Sound Blood Center Research Institute


CLINICAL PROBLEMS WE TREAT

Cancer • Over 1,600,000 new cases of cancer will be diagnosed in the US in 2012 • Over 600,000 people will die • Cancer is a new global pandemic and has the greatest economic impact of all causes of death • ~$14 billion market projected for cancer immunotherapies


CLINICAL PROBLEMS WE TREAT

Infectious Disease • Development of protective vaccines against viruses such as AIDS, SARS, H1N1, Dengue, West Nile virus and others are a societal priority but remain a scientific challenge • The threat of bioterrorism agents such as anthrax and smallpox has heightened the need for the rapid development of effective new vaccines • ~$12billion market for infectious disease vaccines


CLINICAL SOLUTION: TAP Expression Platform

• Cancer cells evade detection by altering expression of an intracellular protein TAP required for directing peptides to the cell surface • Our technology restores TAP expression in a cancer cell and immune recognition resulting in destruction of the cancer cell • Modulating expression of TAP in infectious disease will significantly improve the efficacy of vaccine mediated immune detection


TAP & IMMUNE RECOGNITION (TAP: Transporters Associated with Antigen Presentation)

TAP is down-regulated in tumor cells Restoration of TAP allows immune recognition & killing of cancer cells Antigen & HLA specific


TAP DEFICIENCY: IMMUNE ESCAPE: TUMOR PROGRESSION

X •Many tumors have low or no expression of TAP and in TAP is down-regulated other APM tumor cellscomponents • Absence of TAP affects Restoration of TAP MHC class I Surface allows immune recognition expression & killing of cancer cells • Diminished expression of TAP is associated with Antigen & HLA specific disease progression and metastases resulting in poor prognosis •Vectors reintroducing TAP into Deficient Tumors boost immunity and reduce Tumor Burden

X

X

X X

XX

X

X

X

X


TAP LEVELS AND PATIENT PROGNOSIS IN MELANOMA Kageshita et al (1999) AJP 154, 752


RESTORATION OF TAP EXPRESSION IN LUNG CARCINOMA CMT64 INCREASES TUMOR-SPECIFIC IMMUNE RESPONSE AND SURVIVAL

H-2Kb

150

PBS Y5 AdhTAP1

1. Increase in CMT64 MHC I expression following AdhTAP1 infection

IFNg

0

100

AdhTAP1 Ψ5 Y5 PBS

% Survival

80 60 40

2. Increased survival of tumorbearing mice following administration of AdhTAP1Cancer Res September 1, 2005 65; 7926

20 0 0

20

40 60 Time (days)

Lou et al (2005) Cancer Res., 65, 7926

80

100

link to all publications www.tapimmune.com Lou et al


OUR PRODUCT: NOVEL PLASMID AND Based VIRUS Expression BASED EXPRESSION Novel Plasmid and Virus Vectors VECTORS Tap 1 Peptide Antigen Array (PAA)

Expression Plasmid Tap 2

o Express THREE genes of interest encoding: Tap1, Tap2, and proprietary peptide antigen array (PAA) o Proprietary strategy to enhance PAA translation product copy number o Flexibility to modulate intracellular trafficking and localization of PAA


HER2/neu BREAST CANCER STRATEGY Clinical Collaboration with Mayo Clinic

Licensed IP Mayo clinic

TAP IP

Clinical Prime and boost

• Class I antigen via ‘natural selection’, 373-382 • Class II peptide collection in clinical validation/safety • Vector expression with ‘TAP’ enhanced presentation • Uniquely targeted peptide traffic and processing

• 4 class II Peptides + GMCSF ‘prime’ (Phase I safety) • VV TAP with targeted peptide antigen array


OUR PRODUCT PIPELINE Indication

Product

Stage

Partner

HER2/neu breast cancer TAP10 TAP11

Clinical (Phase I) Mayo Clinic Preclinical

Smallpox

TAP21

Animal efficacy* Mayo Clinic

Melanoma

TAP 20

Preclinical

FHCRC

Emerging pathogens

TAP-platform

Research

Mayo Clinic

*FDA “Animal efficacy rule”


PRODUCT DIFFERENTIATION HER2/neu Product(s) • • • •

Potential to treat ~ 80% of HER2/neu patients Herceptin® ~ $5billion in sales treats ~ 30% HER2/neu patients Combination of proprietary Class I, Class II, and TAP approach for effective CTL killing of tumors and long-acting effect Use in early stage breast cancer

Smallpox/Infectious Disease Product(s) • • •

Safer, more effective, longer shelf-life, lower cost smallpox vaccine Wide application of TAP platform for emerging biodefense threats Rapid response to new biodefense threats & viral pandemics


BUSINESS/PARTNERING STRATEGY • Focus on cancer & infectious disease • Build portfolio of proprietary immunotherapy products • Partner products in preclinical/early clinical development

TapImmune Expertise

External Expertise

Proprietary TAP expression platforms Molecular biology , virology, immunology Vaccine development Development of IP portfolios

Proprietary antigen discovery Clinical, Manufacturing

Partnerships to make vaccines work or work better


EXPECTED MILESTONES 2012/2013 Product TAP10 TAP11 TAP21 TAP 20

Next milestone Phase I trial in HER2/neu breast cancer at Mayo Clinic Safety & immunogenicity Toxicology & manufacturing/IND submission Prime & boost Phase I trial in HER2/neu breast cancer Animal efficacy & Phase I safety on smallpox vaccine Grant funding & strategic collaboration Toxicology & manufacturing IND submission for melanoma

Technology TAP-PAA platform

Build new IP Strategic collaborations Proprietary antigens Additional acquisitions


WHY INVEST IN TAPIMMUNE? • Unique platform solving a key problem in immunotherapy • Strong product pipeline • Multiple partnership possibilities • World-class management & advisory team

• Risk diversification – cancer & infectious disease • Compelling preclinical data • Start of clinical programs • Undervalued and poised for significant growth

An approach with the potential to change lives


Product Design with Vaccinomics in Mind


CONTACT Glynn Wilson Chief Executive Officer gwilson@tapimmune.com

Investor Relations IR@tapimmune.com


Appendix

PUBLICATIONS PATENTS


PEER REVIEWED JOURNAL PUBLICATIONS Pharma Mag March 2011  Novel Targets for Cancer Vaccine Development International Journal of Cancer: 120 (1935-1941) 2007  TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma Science Direct: Vaccine: 25 (2331-2339) 2007  Tumor immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1

PLoS Pathogens: Volume 1 (Issue 4/ e36) December 2005  Using the TAP Component of the Antigen-Processing Machinery as a Molecular Adjuvant Cancer Research 65: (7926-7933) September 1, 2005  Restoration of the Expression of Transporters Associated with Antigen Processing in Lung Carcinoma Increases Tumor-Specific Immune Responses and Survival Cancer Research 16: (7485-7492 ) August 15, 2005  Identification of Mechanisms Underlying Transporter Associated with Antigen Processing Deficiency in Metastatic Murine Carcinomas Journal of Immunology: 172 (5200-5205) May 2004  CTL-Dependent and -Independent Antitumor Immunity Is Determined by the Tumor Not the Vaccine Nature Biotechnology: 18 (515-520) May 2000  TAP expression provides a general method for improving the recognition of malignant cells in vivo


PATENTS • METHOD OF IDENTIFYING MHC-CLASS I RESTRICTED ANTIGENS • METHOD OF ENHANCING EXPRESSION OF AN IMMUNE REPSONSE • LOW DOSE INNOCULATION WITH TAP-I FOR ANTITUMOR IMMUNITY • POXVIRADAE TREATMENT • COMBINATION OF ANTIGEN PROCESSING COMPONENTS ELICITS SURVIVAL IN TUMOR-BEARING ANIMALS  Patents issued in multiple global jurisdictions as recent as Aug 2011  Total of 55 Patent Applications


PATENTS MAYO CLINIC ANTIGENS • Her2/neu class II antigens

• Her2/neu class I antigen • Small pox class II antigens

• Small pox class I antigens • Future collaborative antigens/targets by way of funded discovery/development joint program


tpiv-corporate-presentation